The Uromigos
Episodes
Episode 293: ASCO GU 2024: BRCAaway and CONTACT2
26 Jan 2024
Contributed by Lukas
Kim Chi discussed the prostate cancer oral session at ASCO GU 2024.
Episode 292: ASCO GU 2024: HPN328 - A Tri-Specific T Cell Engager in Prostate Cancer
26 Jan 2024
Contributed by Lukas
Misha Beltran describes the activity of this novel agent in neuroendocrine prostate cancer.
Episode 291: ASCO GU 2024: CONTACT2 - Cabozantinib and Atezolizumab in Prostate Cancer
25 Jan 2024
Contributed by Lukas
Neeraj Agarwal describes the results of this positive randomised Phase 3 trial.
Episode 290: ASCO GU 2024 Preview
17 Jan 2024
Contributed by Lukas
What to look out for in bladder, prostate and renal cancer at this year's meeting.
Episode 289: The Uromigos Paper of the Month - TALAPRO2 in Nature Medicine
15 Jan 2024
Contributed by Lukas
Karim Fizazi discusses the clinical and biomarker components of this data.
Episode 288: APCCC #3: Controversies around Radiotherapy
10 Jan 2024
Contributed by Lukas
Thomas Zilli discusses controversies around radiotherapy in prostate cancer.
Episode 287 APCCC: Early Discontinuation of Therapy in HSPC
04 Jan 2024
Contributed by Lukas
Silke Gillessen and Betrand Tombal discuss the questions which will address this issue in Lugano in March 2024.
Episode 286: APCCC Prostate Cancer Meeting Overview
03 Jan 2024
Contributed by Lukas
Silke Gillessen discusses this biannual meeting taking place in Lugano in March 2024.
Episode 285: Holiday Special: Renal Cancer in 2023
22 Dec 2023
Contributed by Lukas
Cristina Suarez discusses the year in review.
Episode 284: Tres amigas: Lo más destacado del cáncer en urología en 2023
21 Dec 2023
Contributed by Lukas
Elena Castro, Begoña Valerrama y Cristina Suárez analizan lo más destacado del cáncer en urología en 2023
Episode 283: Holiday Special: Prostate Cancer in 2023
20 Dec 2023
Contributed by Lukas
Tanya Dorff discusses her favourite prostate cancer studies of the year.
Episode 282: Holiday Special: Bladder Cancer in 2023
13 Dec 2023
Contributed by Lukas
Kala Sridhar discusses all the key trials in 2023. She also reveals her favourite Xmas song.
Episode 281: The Uromigos Paper of the Month - Lu-177 with Pembrolizumab in Prostate Cancer
08 Dec 2023
Contributed by Lukas
Rahul Aggarwal describes his phase 1/2 study with only 1 cycle of Lu-177 in CRPC.
Episode 280: IKCS 2023 Overview
16 Nov 2023
Contributed by Lukas
Tian Zhang discusses this fabulous renal cancer meeting. Belzutifan is covered too.
An apology
13 Nov 2023
Contributed by Lukas
Tom and Brian apologise for the unacceptable words and images which were broadcast by hackers during the Uromigos livestream last week. We’re really...
Episode 279: Management of IO-resistant RCC at #UromigosLive 2023
06 Nov 2023
Contributed by Lukas
Monty Pal, Toni Chouieri, and Tian Zhang join Tom and Brian to discuss CONTACT-03, TiNivo-2, IO-based therapy, and more. Recorded live at Uromigos Liv...
Episode 278: Current and Future Status of Radioligand Therapy at #UromigosLive 2023
04 Nov 2023
Contributed by Lukas
Brian is joined by Neeraj Agarwal, Tanya Dorff, Rana McKay, and Michael Morris to review the state of radioligand therapy. The panel examines primary ...
Episode 277: NMIBC Discussion at #UromigosLive 2023
04 Nov 2023
Contributed by Lukas
Tom is joined by Sam Chang, Sia Daneshmand, and Petros Grivas to discuss new therapies in non-muscle invasive bladder cancer, including those for BCG-...
Episode 276: ESMO 2023 Highlights
28 Oct 2023
Contributed by Lukas
Silke Gillessen joins Tom and Brian to give a summary of the meeting,
Episode 275: Live meeting preview for #UromigosLive 2023 in Nashville
27 Oct 2023
Contributed by Lukas
Brian and Tom discuss the benefits and risks of participating in the upcoming meeting . Uncertainty around it’s success are highlighted . Methods of...
Episode 274: ESMO 2023 STEAP1/BiTE in CRPC shows promise
27 Oct 2023
Contributed by Lukas
Kevin Kelly described a Six-transmembrane epithelial antigen of the prostate 1 (STEAP1) bispecific T cell engager showing activity in a phase 1 trial ...
Episode 273: ESMO 2023 - Toripalimab and axitinib in clear cell RCC
26 Oct 2023
Contributed by Lukas
Toripalimab plus axitinib as first-line treatment option for advanced RCC by Xinan Sheng
Episode 272: ESMO 2023 - EV302 and CM901 in 1st line bladder cancer
22 Oct 2023
Contributed by Lukas
Michiel van der Heijden and Tom discuss EV302 (EVP) and CM901 (chemo/nivo)
Episode 271: ESMO 2023 - THOR: Erdafitinib in bladder cancer
22 Oct 2023
Contributed by Lukas
Yohann Loriot described the 2 Thor randomised phase 3 studies
Episode 270: ESMO 2023 - Belzutifan in renal cancer
21 Oct 2023
Contributed by Lukas
Lisa Pickering discusses the 2 randomised trial and the 1st line combination study in renal cancer
Episode 269: ESMO 2023 - antibody drug conjugate doublets in UC
21 Oct 2023
Contributed by Lukas
Brad McGregor discuses the DAD trial exploring this combo for the 1st time
Episode 268: ESMO 2023 - Enzalutamide and 177Lu-PSMA-617 in CRPC with Louise Emmett
20 Oct 2023
Contributed by Lukas
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 19...
Episode 267: ESMO preview - things to look out for at the meeting
11 Oct 2023
Contributed by Lukas
Silke Gillessen, Brian and Tom look at ESMO 2023 GU track and beyond
Episode 266: Radiotherapy for prostate cancer
10 Oct 2023
Contributed by Lukas
Nick James discusses the optimal patients for radiotherapy and his approach to perioperative hormone therapy
Episode 265: Brachytherapy with Jeff Michalski
03 Oct 2023
Contributed by Lukas
Paper of the month: a randomised trial of brachytherapy vs external beam.
Episode 264: Prostatectomy vs RT vs surveillance- the PROTECT trial
27 Sep 2023
Contributed by Lukas
Jim Catto describes the 17 yr follow up data from this large prostate cancer study.
Episode 263: Toni Choueiri and papillary renal cancer
20 Sep 2023
Contributed by Lukas
We describes progress in system therapy for advanced papillary RCC. Opportunities and challenges around personalised therapy are discussed
Episode 262: Paper of the month abiraterone +/- cabazitaxel in CRPC.
12 Sep 2023
Contributed by Lukas
Susan Slovin describes her JCO investigator initiated R2 study which show the addition of cabazitaxel to abiraterone may be of benefit in CRPC
Episode 261: part 2 ctDNA in bladder cancer
04 Sep 2023
Contributed by Lukas
Matt Galsky completes the discussion on the rapidly moving topic.
Episode 260: Celeste Simon: how to make a career in translation science work.
30 Aug 2023
Contributed by Lukas
Celeste shares her thoughts on her career in the lab, collaboration and working with clinicians. She also talks about things that went well and things...
Episode 259: Cystectomy for bladder cancer
24 Aug 2023
Contributed by Lukas
Jim Catto defends the virtues of cystectomy after last weeks radiotherapy for MIBC podcast with Ananya
Episode 258: Curative radiotherapy for bladder cancer: Golden Ticket Winner #1
15 Aug 2023
Contributed by Lukas
Ananya Choudhury discussed the evidence for RT/TMT instead of surgery in muscle invasive bladder cancer. Regina Barragan-Carrillo (Golden Ticket Winne...
Episode 257: Chana Weinstock from the FDA
07 Aug 2023
Contributed by Lukas
Chana discusses her role at the FDA, how it functions and answers questions on topical issues.
Episode 256: ctDNA in urothelial studies.
27 Jul 2023
Contributed by Lukas
Mat Galski discusses the past, present and future of ctDNA in this disease.
Episode 255: How to get an academic paper accepted
26 Jul 2023
Contributed by Lukas
Walt Stadler gives tips to writing papers and navigating the review process.
Episode 254: New RCC studies at KCRS 2023 with Laurence Albiges
17 Jul 2023
Contributed by Lukas
Laurence Albiges discusses biomarker studies, new combinations and new therapies which were covered in the KCRS23 meeting in the ‘new studies' s...
Episode 253: Patients' perspectives on adjuvant and 1st line RCC
13 Jul 2023
Contributed by Lukas
Rachel Giles (chair of IKCC) describes her data from patients on these topics in RCC
Episode 252: Talazoparib and its FDA approval in CRPC
04 Jul 2023
Contributed by Lukas
Neeraj Agarwal describes the TALAPRO-2 study and relevance of the HRR biomarker in the 2 cohorts presented. A discussion regarding other PARPis and BR...
Episode 251: Final part of VEGF/TKI vs IPI/NIVO discussion
26 Jun 2023
Contributed by Lukas
Meredith Regan and David McDermott try to make sense of it all but are unexpectedly interrupted. PFS2 and TFS are covered along with previously discus...
Episode 250: Bob Motzer discusses IPI/Nivo vs VEGF/PD1
18 Jun 2023
Contributed by Lukas
After the discussion with Mike Atkins, Bob Motzer gives his perspective of the 1st line renal cancer situation .
Episode 249: ASCO 2023 emergency podcast IPI/NIVO vs VEGF/PD1 in kidney cancer
18 Jun 2023
Contributed by Lukas
Prompted by a question during the oral kidney cancer session at ASCO, Mike Atkins explains his position. Disagreement prevails.
Episode 248: ASCO23 GU highlights
14 Jun 2023
Contributed by Lukas
Silke Gillessen joins Brian and Tom for a quick round up.
Episode 246: ASCO 2023: EV pembro and erdafitinib +/- cetrelimab in 1st line UC
05 Jun 2023
Contributed by Lukas
Shilpa Gupta discussed these 2 oral abstracts from ASCO
Episode 245: ASCO 2023 - CONTACT-03 cabozantinib +/- atezolizumab in renal cancer
05 Jun 2023
Contributed by Lukas
Toni Choueiri describes the results of this renal cancer trial exploring rechallange with immune therapy
Episode 244: ASCO 2023 PEACE-1 in CRPC
05 Jun 2023
Contributed by Lukas
Karim Fizazi described the radiotherapy component of this study.
Episode 243: ASCO 2023 TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
05 Jun 2023
Contributed by Lukas
ASCO 2023: TALAPRO-2: Phase 3 Study of Talazoparib + Enzalutamide
Episode 242: ASCO 2023 THOR study - erdafitinib vs chemo in bladder cancer
05 Jun 2023
Contributed by Lukas
yohann Loriot discusses this practice changing trial
Episode 241: Statistics for clinical trials
01 Jun 2023
Contributed by Lukas
Meredith Regan describes how best to interpret KM curves and comparative analysis.
Episode 240: Preview of GU Cancer at ASCO 2023
30 May 2023
Contributed by Lukas
A look forward to bladder, kidney and prostate cancer sessions at ASCO 2023
Episode 239: The STAMPEDE trial
22 May 2023
Contributed by Lukas
Nick James describes the success this practice changing multi arm prostate study with an adaptive design
Episode 238: Paper of the month: Biomarkers for neoadjuvant PD(L)1 therapy
14 May 2023
Contributed by Lukas
Josh Meeks describes his teams Nature Communications paper (including 11 supplementary figures).
Episode 237: 2023 AUA Highlights
09 May 2023
Contributed by Lukas
Tom, who failed to invite a guest, quizzes Brian on the new data from the meeting he attended.
Episode 236: ODAC for olaparib
02 May 2023
Contributed by Lukas
Jorge A. Garcia, MD, FACP, chairperson of the Oncologic Drugs Advisory Committee (ODAC) for the US Food & Drug Administration, shared insight on the r...
Episode 235: Danny Heng and the IMDC classification in renal cancer
24 Apr 2023
Contributed by Lukas
Daniel Heng, MD, MPH, FRCPC, joins us to discuss IMDC classification for renal cell carcinoma and the treatment of patients with favorable risk diseas...
Episode 234: Amar Kishan, MD, on Neoadjuvant or Adjuvant Radiotherapy for Prostate Cancer
19 Apr 2023
Contributed by Lukas
In the first part of our Hollywood tour, Amar Kishan, MD, joins us to discuss his recent meta-analysis published in the Journal of Clinical Oncology o...
Episode 233: Destaques da 14ª reunião internacional brasileira de câncer urológico
15 Apr 2023
Contributed by Lukas
Karine Trindade e Fernando Maluf dão uma visão geral da reunião e dos avanços na investigação do câncer no Brasil
Episode 232: Belzutifan in early and late renal cancer
14 Apr 2023
Contributed by Lukas
We’re joined by Toni Choueiri, MD, and Brian Shuch, MD, to discuss several studies on the use of belzutifan alone and in combination with other ...
Episode 231: Ursula Vogl, MD in the Rising Star Series
05 Apr 2023
Contributed by Lukas
Ursula Vogl, MD, discusses her career in the prostate cancer and renal cell cancer fields, as well as recent projects that she has contributed to incl...
Episode 230: FGFR Inhibition in NMIBC With Sia Daneshmand
28 Mar 2023
Contributed by Lukas
Sia Daneshmand, MD, joins the show to review 2 studies on the use of erdafitinib for the treatment of non-muscle invasive bladder cancer, including th...
Episode 229: Kala Sridhar, MD on PET in Early Bladder Cancer
20 Mar 2023
Contributed by Lukas
Kala Sridhar, MD discusses her recent work on the PET MUSE study on the impact of PET imaging in muscle-invasive urothelial carcinoma, as well as a ne...
Episode 228: Karine Tawagi, MD in the Rising Star Series
15 Mar 2023
Contributed by Lukas
Karine Tawagi, MD, Assistant Professor of Clinical Medicine and Associate Fellowship Program Director at the University of Illinois in Chicago, joins ...
Episode 227: 2023 ASCO GU Bladder Highlights and Paper of the Month with Michiel Van der Heijden
06 Mar 2023
Contributed by Lukas
Michiel Van der Heijden, MD, PhD, joined Tus to review bladder cancer presentations from the 2023 ASCO GU Cancers Symposium, including the phase 1B NA...
Episode 226: 2023 ASCO GU Prostate and RCC Highlights With Dan George
27 Feb 2023
Contributed by Lukas
The Uromigos are joined by Daniel George, MD, to review RCC and prostate cancer presentations from the 2023 ASCO GU Cancers Symposium, including tripl...
Episode 225: ASCO GU 2023: Brian Shuch, MD discusses the ZIRCON Phase III Study of girentuximab PET/CT imaging in RCC
20 Feb 2023
Contributed by Lukas
Brian Shuch, MD, discusses the ZIRCON Phase III kidney cancer imaging study to determine the identification and characterization abilities of TLX250-C...
Episode 224: ASCO GU 2023: discussing miR371 for Germ Cell Tumors with Christian Kollmannsberger
20 Feb 2023
Contributed by Lukas
The Uromigos are joined by Christian Kollmannsberger, MD, FRCPC, to discuss his presentation at the ASCO GU Cancers Symposium on utilizing miR371 as a...
Episode 223: ASCO GU 2023: Discussing KEYNOTE-057 with Andrea Necchi, MD
17 Feb 2023
Contributed by Lukas
The Uromigos met with Andrea Necchi, MD at the 2023 ASCO GU Cancers Symposium to discuss results of the phase 2 KEYNOTE-057 study on the use of pembro...
Episode 222: ASCO GU 2023: New Data From IMvigor130 with Enrique Grande, MD
17 Feb 2023
Contributed by Lukas
Enrique Grande, MD, PhD, Msc, met with The Uromigos at the 2023 ASCO GU Cancers Symposium to discuss the phase 3 IMvigor130 study that examined 3 trea...
Episode 221: ASCO GU 2023: Matt Galsky, MD Gives an Update on the CheckMate 274 Trial
17 Feb 2023
Contributed by Lukas
Matt Galsky, MD discusses several abstracts presented at the 2023 ASCO GU Cancers Symposium on perioperative nivolumab for urothelial cancer, includin...
Episode 220: ASCO GU 2023: Discussing PARPi for CRPC with Michael Morris, MD
17 Feb 2023
Contributed by Lukas
The Uromigos met with Michael Morris, MD while at the 2023 ASCO GU Cancers Symposium to discuss PARP inhibition for castration-resistant prostate canc...
Episode 219: ASCO GU 2023: Neeraj Agarwal, MD, FASCO Discusses the TALAPRO-2 study
17 Feb 2023
Contributed by Lukas
Neeraj Agarwal, MD, FASCO, describes the data from the TALAPRO-2 study on combination talazoparib and enzalutamide for metastatic castration-resistant...
Episode 218: Discussing The Cost of Cancer Drugs With Daniel Goldstein, MD
07 Feb 2023
Contributed by Lukas
The Uromigos discuss the cost of quality adjusted life years with Daniel Goldstein, MD, Senior Physician at the Davidoff Cancer Center of Rabin Medica...
Episode 217: Rising Star: Vadim Koshkin and ADCs
03 Feb 2023
Contributed by Lukas
Peter O'Donnell makes a guest appearance.
Episode 216: ADCs in Bladder Cancer With Petros Grivas, MD, PhD
30 Jan 2023
Contributed by Lukas
Petros Grivas, MD, PhD joins The Uromigos to discuss the use of antibody drug conjugates in bladder cancer, including enfortumab vedotin (EV) and the ...
Episode 215: Resumen cáncer de próstata y vejiga reunión Canarias
21 Jan 2023
Contributed by Lukas
Resumen cáncer de próstata y vejiga reunión Canarias
Episode 214: Resumen de la reunión en las Islas Canarias sobre cáncer renal
21 Jan 2023
Contributed by Lukas
Resumen de la reunión en las Islas Canarias sobre cáncer renal
Episode 213: IL-15RaFc superagonist in NMIBC
09 Jan 2023
Contributed by Lukas
Sam Chang describes the data for this agent in bladder cancer.
Episode 212: What's coming in GU Cancers in 2023
02 Jan 2023
Contributed by Lukas
What's happening this year in GU cancer.
Episode 211: CAR-T cell therapy in RCC
29 Dec 2022
Contributed by Lukas
Monty Pal describes his recent study presented at SITC.
Episode 210: Christmas Prostate Cancer Debate - olaparib and abiraterone in selected or unselected patients
22 Dec 2022
Contributed by Lukas
Dan George and Silke Gillessen disagree amicably.
Episode 209: Christmas Bladder Cancer Debate - Cisplatin vs carboplatin in bladder cancer
17 Dec 2022
Contributed by Lukas
Matt Galski defends cisplatin admirably.
Episode 208: Christmas Kidney Cancer Debate - Ipilimumab in renal cancer
12 Dec 2022
Contributed by Lukas
David McDermott and Brian Rini debate this topic.
Episode 207: Editorial on COSMIC-313
05 Dec 2022
Contributed by Lukas
Pavlos Msaouel discusses some of the statistical components of this and other RCC studies.
Episode 206: Dan Shapiro in the Rising Star series
28 Nov 2022
Contributed by Lukas
Dan talks about his work in rare renal cancer.
Episode 205: Paper of the Month - Nab-paclitaxel and pembrolizumab in bladder cancer
21 Nov 2022
Contributed by Lukas
Andrea Necchi describes his paper and the future of this combination.
Episode 204: Scott Haake in the Rising Star series
14 Nov 2022
Contributed by Lukas
Scott discusses ctDNA in RCC.
Episode 203: Renee Saliby in the Rising Star series
14 Nov 2022
Contributed by Lukas
Validating the Immotion151 Signatures
Episode 202: The Uromigos Paper of the Month - Docetaxel with or without continuous enza in CRPC
07 Nov 2022
Contributed by Lukas
Axel Merseburger describes the results of this randomised trial in Lancet Oncology.
Episode 201: PARPi in CRPC
01 Nov 2022
Contributed by Lukas
Rob Jones gives his views on the current data sets.
Episode 200: Chromophobe renal cancer
25 Oct 2022
Contributed by Lukas
Lisa Henske discusses her latest paper on the biology of the disease.
Episode 199: The Uromigos Paper of the Month - FGFR inhibition in bladder cancer
17 Oct 2022
Contributed by Lukas
Randomised trial of rogaratinib in bladder cancer with Cora Sternberg.
Episode 198: The RADICALS trial in prostate cancer
07 Oct 2022
Contributed by Lukas
Silke Gillessen and Nick James discuss the results of this randomised trial exploring duration of adjuvant/salvage androgen ablation with XRT in prost...
Episode 197: The Uromigos Nashville 2022
29 Sep 2022
Contributed by Lukas
Here are the details for the Livestream portions of The Uromigos Nashville meeting! Bladder Cancel Panel on September 30, 1-2PM CST https://yout...
Episode 196: The COSMIC-313 Trial cabo/ipi/nivo in 1st line renal cancer
14 Sep 2022
Contributed by Lukas
Toni Choueiri describes the study.
Episode 195 ESMO 2022: EV Pembrolizumab in 1st line bladder cancer
13 Sep 2022
Contributed by Lukas
Peter O'Donnell describes the study.
Episode 194 ESMO 2022: Pegylated il-2 + nivolumab in renal cancer
12 Sep 2022
Contributed by Lukas
Nizar Tannir describes this randomised phase 3 study presented at ESMO.